Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias

References

• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–183. doi:10.1038/nrc1567
   PubMed Web of Science ®Google Scholar
• Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127(4):642–650. doi:10.1309/B4NVER1AJJ84CTUU
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of Haematolymphoid tumours: myeloid and histiocytic/Dendritic Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01613-1
   Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–979. doi:10.1124/jpet.105.084145
   PubMed Web of Science ®Google Scholar
• Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447–1459. doi:10.1016/S0140-6736(13)62120-0
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86(12):2632–2641. doi:10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117–125. doi:10.1016/S1535-6108(02)00096-X
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123(22):4391–4402. doi:10.1002/cncr.30864
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719. doi:10.1182/blood-2015-02-627935
   PubMed Web of Science ®Google Scholar
• Fielding AK. Philadelphia-positive acute lymphoblastic leukemia–is bone marrow transplant still necessary? Biol Blood Marrow Transplant. 2011;17(1 Suppl):S84–S88. doi:10.1016/j.bbmt.2010.11.023
   PubMed Web of Science ®Google Scholar
• Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127(4):642–650. doi:10.1309/B4NVER1AJJ84CTUU
   PubMed Web of Science ®Google Scholar
• Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res. 2004;28(6):579–586. doi:10.1016/j.leukres.2003.10.027
   PubMed Web of Science ®Google Scholar
• Shimizu H, Yokohama A, Hatsumi N, et al. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014;93(4):297–301. doi:10.1111/ejh.12343
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409. doi:10.1182/blood-2017-06-788786
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi:10.1182/blood.2020004856
   PubMed Web of Science ®Google Scholar
• Cang S, Iragavarapu C, Savooji J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8:129. doi:10.1186/s13045-015-0224-3
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak PY, Mu H, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8(355):355ra117. doi:10.1126/scitranslmed.aag1180
   PubMed Web of Science ®Google Scholar
• Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8(354):354ra114. doi:10.1126/scitranslmed.aaf5309
   PubMed Web of Science ®Google Scholar
• Wang H, Yang C, Shi T, et al. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12(1):20. doi:10.1038/s41408-022-00621-9
   PubMed Web of Science ®Google Scholar
• Massimino M, Vigneri P, Stella S, et al. Combined inhibition of Bcl2 and Bcr-Abl1 exercises Anti-Leukemia activity but does Not eradicate the primitive Leukemic cells. J Clin Med. 2021;10(23):5606. doi:10.3390/jcm10235606
   PubMed Web of Science ®Google Scholar
• Short NJ, Konopleva M, Kadia T, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96(7):E229–E232. doi:10.1002/ajh.26175
   PubMed Web of Science ®Google Scholar
• Maiti A, Franquiz MJ, Ravandi F, et al. Venetoclax and BCR-ABL Tyrosine Kinase inhibitor combinations: outcome in patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020;143(6):567–573. doi:10.1159/000506346
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• FDA.gov [Internet]. [cited 2020 Oct 16]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia.
   Google Scholar
• Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657–1665. doi:10.1038/leu.2014.44
   PubMed Web of Science ®Google Scholar
• Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91(12):1861–1870. doi:10.1007/s00277-012-1537-8
   PubMed Web of Science ®Google Scholar
• Jin S, Cojocari D, Purkal JJ, et al. 5-Azacitidine induces NOXA to prime AML cells for Venetoclax-Mediated apoptosis. Clin Cancer Res. 2020;26(13):3371–3383. doi:10.1158/1078-0432.CCR-19-1900
   PubMed Web of Science ®Google Scholar
• Abaza Y, Kantarjian H, Alwash Y, et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020;95(11):1288–1295. doi:10.1002/ajh.25939
   PubMed Web of Science ®Google Scholar
• Saxena K, Jabbour E, Issa G, et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021;14(1):94. doi:10.1186/s13045-021-01106-1
   PubMed Web of Science ®Google Scholar